Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Non-muscle-invasive bladder cancer, drawn from the whole corpus: 38 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Recurrent BCG shortages.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Predicting who will progress to muscle invasion.
The burden and cost of lifelong cystoscopy.
Comparing the new bladder-sparing options with each other and with cystectomy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
BCG-unresponsive NMIBC with CIS; 28 May 2026 (conditional)
BCG-unresponsive NMIBC with CIS, with BCG; 16 Feb 2026 (conditional)
BCG-unresponsive high-risk NMIBC with CIS, with or without papillary tumours
Recurrent low-grade intermediate-risk NMIBC (intravesical gel)
BCG-unresponsive NMIBC with CIS ± papillary tumours, with BCG